<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" class="marks" width="922" height="239" viewBox="0 0 922 239"><rect width="922" height="239" fill="white"/><g fill="none" stroke-miterlimit="10" transform="translate(46,15)"><g class="mark-group role-frame root" role="graphics-object" aria-roledescription="group mark container"><g transform="translate(0,0)"><path class="background" aria-hidden="true" d="M0,0h0v180h0Z"/><g><g class="mark-group role-scope concat_0_group" role="graphics-object" aria-roledescription="group mark container"><g transform="translate(0,0)"><path class="background" aria-hidden="true" d="M0,0h150v180h-150Z" stroke="#ddd" stroke-width="3"/><g><g class="mark-group role-axis" role="graphics-symbol" aria-roledescription="axis" aria-label="X-axis titled 'API_3x' for a linear scale with values from 0 to 10"><g transform="translate(0.5,180.5)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rule role-axis-tick" pointer-events="none"><line transform="translate(0,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(30,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(60,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(90,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(120,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(150,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-label" pointer-events="none"><text text-anchor="start" transform="translate(0,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0</text><text text-anchor="middle" transform="translate(30,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">2</text><text text-anchor="middle" transform="translate(60,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">4</text><text text-anchor="middle" transform="translate(90,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">6</text><text text-anchor="middle" transform="translate(120,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">8</text><text text-anchor="end" transform="translate(150,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">10</text></g><g class="mark-text role-axis-title" pointer-events="none"><text text-anchor="middle" transform="translate(75,34)" font-family="sans-serif" font-size="11px" font-weight="bold" fill="#000" opacity="1">API_3x</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-group role-axis" role="graphics-symbol" aria-roledescription="axis" aria-label="Y-axis titled 'API_5x' for a linear scale with values from 0 to 10"><g transform="translate(0.5,0.5)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rule role-axis-tick" pointer-events="none"><line transform="translate(0,180)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,144)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,108)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,72)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,36)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,0)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-label" pointer-events="none"><text text-anchor="end" transform="translate(-7,184)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0</text><text text-anchor="end" transform="translate(-7,148)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">2</text><text text-anchor="end" transform="translate(-7,112)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">4</text><text text-anchor="end" transform="translate(-7,76)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">6</text><text text-anchor="end" transform="translate(-7,39.99999999999999)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">8</text><text text-anchor="end" transform="translate(-7,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">10</text></g><g class="mark-text role-axis-title" pointer-events="none"><text text-anchor="middle" transform="translate(-26.572265625,90) rotate(-90) translate(0,-2)" font-family="sans-serif" font-size="11px" font-weight="bold" fill="#000" opacity="1">API_5x</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-symbol role-mark concat_0_layer_0_marks" role="graphics-object" aria-roledescription="symbol mark container"><path aria-label="API_3x: 10; API_5x: 10; Statements: a. Association with type I interferon responses; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(150,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; API_5x: 5.8; Statements: b. Association with type II interferon responses; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,75.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; API_5x: 6.2; Statements: c. Association with type III interferon responses; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(85,68.4)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; API_5x: 8.4; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(130,28.799999999999986)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; API_5x: 3; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,125.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; API_5x: 6; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(95,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.33333333333; API_5x: 4; Statements: g. Known drug target; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(50.00000000000001,108)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.33333333333; API_5x: 8.2; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(125,32.400000000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; API_5x: 8.4; Statements: a. Association with type I interferon responses; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(130,28.799999999999986)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; API_5x: 5.4; Statements: b. Association with type II interferon responses; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,82.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; API_5x: 5.6; Statements: c. Association with type III interferon responses; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(45,79.20000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; API_5x: 7; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(105,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; API_5x: 2.4; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(30,136.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; API_5x: 5.6; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(80,79.20000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; API_5x: 1.4; Statements: g. Known drug target; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(15,154.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; API_5x: 6.4; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(85,64.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; API_5x: 8.2; Statements: a. Association with type I interferon responses; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(130,32.400000000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; API_5x: 5.8; Statements: b. Association with type II interferon responses; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,75.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; API_5x: 5.6; Statements: c. Association with type III interferon responses; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,79.20000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; API_5x: 7.6; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(105,43.199999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; API_5x: 2.6; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(30,133.2)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; API_5x: 5.2; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(80,86.39999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; API_5x: 1.6; Statements: g. Known drug target; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(20,151.2)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; API_5x: 6.8; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(90,57.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; API_5x: 1.8; Statements: a. Association with type I interferon responses; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(40,147.60000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; API_5x: 1.8; Statements: b. Association with type II interferon responses; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,147.60000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; API_5x: 1.2; Statements: c. Association with type III interferon responses; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(15,158.4)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; API_5x: 4.2; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(70,104.39999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; API_5x: 0.8; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(10,165.6)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; API_5x: 3.2; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,122.39999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; API_5x: 1; Statements: g. Known drug target; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(15,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; API_5x: 2.6; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(40,133.2)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; API_5x: 6.4; Statements: a. Association with type I interferon responses; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,64.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9; API_5x: 10; Statements: b. Association with type II interferon responses; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(135,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; API_5x: 5; Statements: c. Association with type III interferon responses; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(70,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; API_5x: 8.2; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(120,32.400000000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; API_5x: 2.8; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(40,129.6)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; API_5x: 5.4; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(80,82.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; API_5x: 1.8; Statements: g. Known drug target; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,147.60000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; API_5x: 7.2; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,50.400000000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; API_5x: 6; Statements: a. Association with type I interferon responses; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(85,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; API_5x: 8.2; Statements: b. Association with type II interferon responses; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(95,32.400000000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; API_5x: 4.8; Statements: c. Association with type III interferon responses; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,93.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; API_5x: 7.4; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,46.800000000000004)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; API_5x: 2.2; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(30,140.4)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; API_5x: 5.2; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(75,86.39999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; API_5x: 1.2; Statements: g. Known drug target; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(15,158.4)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; API_5x: 6; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(75,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; API_5x: 6.6; Statements: a. Association with type I interferon responses; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,61.20000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.33333333333; API_5x: 8.2; Statements: b. Association with type II interferon responses; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(109.99999999999999,32.400000000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.33333333333; API_5x: 5; Statements: c. Association with type III interferon responses; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(65,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.33333333333; API_5x: 8; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(125,35.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; API_5x: 2.8; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(35,129.6)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; API_5x: 5.2; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(75,86.39999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; API_5x: 1.6; Statements: g. Known drug target; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(20,151.2)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; API_5x: 6.8; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,57.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; API_5x: 7.2; Statements: a. Association with type I interferon responses; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(120,50.400000000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; API_5x: 6; Statements: b. Association with type II interferon responses; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(75,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; API_5x: 4.2; Statements: c. Association with type III interferon responses; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(45,104.39999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; API_5x: 6.8; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(105,57.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; API_5x: 2.4; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(30,136.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; API_5x: 5.2; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(90,86.39999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; API_5x: 1.2; Statements: g. Known drug target; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(15,158.4)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; API_5x: 6; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(75,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.33333333333; API_5x: 10; Statements: a. Association with type I interferon responses; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(140,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; API_5x: 5; Statements: b. Association with type II interferon responses; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(45,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; API_5x: 5.6; Statements: c. Association with type III interferon responses; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(80,79.20000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; API_5x: 8.4; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(120,28.799999999999986)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; API_5x: 3; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(35,125.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; API_5x: 6.4; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(75,64.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; API_5x: 2; Statements: g. Known drug target; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(35,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; API_5x: 7.6; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(105,43.199999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.33333333333; API_5x: 9; Statements: a. Association with type I interferon responses; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(140,17.999999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; API_5x: 6.6; Statements: b. Association with type II interferon responses; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(75,61.20000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; API_5x: 6.2; Statements: c. Association with type III interferon responses; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(75,68.4)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.66666666667; API_5x: 7.8; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(115.00000000000001,39.599999999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; API_5x: 3; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(45,125.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; API_5x: 5.4; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(90,82.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; API_5x: 1.8; Statements: g. Known drug target; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(30,147.60000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; API_5x: 6.6; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,61.20000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9; API_5x: 9; Statements: a. Association with type I interferon responses; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(135,17.999999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4; API_5x: 6; Statements: b. Association with type II interferon responses; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(60,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.33333333333; API_5x: 5.8; Statements: c. Association with type III interferon responses; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(65,75.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; API_5x: 7.8; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(105,39.599999999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; API_5x: 3.2; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(30,122.39999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; API_5x: 5.8; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(85,75.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; API_5x: 2; Statements: g. Known drug target; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; API_5x: 6.8; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(90,57.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 10; API_5x: 10; Statements: a. Association with type I interferon responses; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(150,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; API_5x: 5.4; Statements: b. Association with type II interferon responses; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(45,82.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; API_5x: 7.2; Statements: c. Association with type III interferon responses; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(90,50.400000000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; API_5x: 8.8; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(130,21.59999999999998)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4; API_5x: 3.6; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(60,115.2)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; API_5x: 6.4; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(95,64.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; API_5x: 2.4; Statements: g. Known drug target; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(30,136.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.66666666667; API_5x: 7.8; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(115.00000000000001,39.599999999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; API_5x: 2; Statements: a. Association with type I interferon responses; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(45,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; API_5x: 2; Statements: b. Association with type II interferon responses; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(30,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; API_5x: 1; Statements: c. Association with type III interferon responses; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(15,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; API_5x: 4.4; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(75,100.79999999999998)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; API_5x: 1; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.33333333333; API_5x: 3.2; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(50.00000000000001,122.39999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; API_5x: 1.6; Statements: g. Known drug target; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(20,151.2)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; API_5x: 3; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(45,125.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.66666666667; API_5x: 9.4; Statements: a. Association with type I interferon responses; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(144.99999999999997,10.79999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; API_5x: 7.4; Statements: b. Association with type II interferon responses; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(80,46.800000000000004)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; API_5x: 6.4; Statements: c. Association with type III interferon responses; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(75,64.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.33333333333; API_5x: 8.4; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(125,28.799999999999986)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; API_5x: 3.8; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(45,111.6)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; API_5x: 5.6; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(105,79.20000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; API_5x: 2.6; Statements: g. Known drug target; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(30,133.2)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.33333333333; API_5x: 7.2; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(109.99999999999999,50.400000000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.66666666667; API_5x: 6.8; Statements: a. Association with type I interferon responses; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(115.00000000000001,57.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; API_5x: 5.2; Statements: b. Association with type II interferon responses; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,86.39999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; API_5x: 4; Statements: c. Association with type III interferon responses; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(35,108)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; API_5x: 6.6; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(95,61.20000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; API_5x: 2.2; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(20,140.4)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; API_5x: 5; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(75,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; API_5x: 2.4; Statements: g. Known drug target; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(40,136.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; API_5x: 5.6; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(70,79.20000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; API_5x: 6.4; Statements: a. Association with type I interferon responses; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(105,64.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; API_5x: 5.2; Statements: b. Association with type II interferon responses; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(75,86.39999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.33333333333; API_5x: 3.8; Statements: c. Association with type III interferon responses; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(50.00000000000001,111.6)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; API_5x: 7.4; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(120,46.800000000000004)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; API_5x: 2.6; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(30,133.2)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; API_5x: 5.6; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(85,79.20000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4; API_5x: 4.2; Statements: g. Known drug target; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(60,104.39999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; API_5x: 6.6; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(105,61.20000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; API_5x: 7.2; Statements: a. Association with type I interferon responses; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(120,50.400000000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; API_5x: 4.8; Statements: b. Association with type II interferon responses; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(45,93.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; API_5x: 3.4; Statements: c. Association with type III interferon responses; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(30,118.80000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; API_5x: 7; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(105,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; API_5x: 2.2; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(15,140.4)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; API_5x: 5.8; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(75,75.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; API_5x: 1.2; Statements: g. Known drug target; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(10,158.4)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; API_5x: 5.8; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(90,75.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; API_5x: 1.4; Statements: a. Association with type I interferon responses; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(10,154.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; API_5x: 1.4; Statements: b. Association with type II interferon responses; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(10,154.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; API_5x: 1; Statements: c. Association with type III interferon responses; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(10,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; API_5x: 2.8; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(40,129.6)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; API_5x: 0.4; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(10,172.79999999999998)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; API_5x: 2.8; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(35,129.6)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0; API_5x: 0.2; Statements: g. Known drug target; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(0,176.4)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; API_5x: 1.8; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(20,147.60000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 10; API_5x: 10; Statements: a. Association with type I interferon responses; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(150,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.66666666667; API_5x: 10; Statements: b. Association with type II interferon responses; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(144.99999999999997,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; API_5x: 8; Statements: c. Association with type III interferon responses; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(120,35.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.33333333333; API_5x: 9; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(140,17.999999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; API_5x: 5.2; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(80,86.39999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; API_5x: 7; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(105,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; API_5x: 5.4; Statements: g. Known drug target; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(70,82.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; API_5x: 8.8; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(130,21.59999999999998)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9; API_5x: 8.4; Statements: a. Association with type I interferon responses; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(135,28.799999999999986)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; API_5x: 6.6; Statements: b. Association with type II interferon responses; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(85,61.20000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4; API_5x: 4.8; Statements: c. Association with type III interferon responses; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(60,93.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; API_5x: 7.6; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(120,43.199999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; API_5x: 2.8; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(40,129.6)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; API_5x: 5.4; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,82.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; API_5x: 1.8; Statements: g. Known drug target; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,147.60000000000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; API_5x: 6.8; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(95,57.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9; API_5x: 9; Statements: a. Association with type I interferon responses; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(135,17.999999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; API_5x: 6.2; Statements: b. Association with type II interferon responses; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(70,68.4)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.33333333333; API_5x: 4.6; Statements: c. Association with type III interferon responses; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(50.00000000000001,97.2)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; API_5x: 7.8; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(120,39.599999999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; API_5x: 2.4; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(35,136.8)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; API_5x: 5.8; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(85,75.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; API_5x: 2.2; Statements: g. Known drug target; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,140.4)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; API_5x: 6.8; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,57.60000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/></g><g class="mark-text role-mark concat_0_layer_1_marks" role="graphics-object" aria-roledescription="text mark container"><text text-anchor="start" transform="translate(10,14)" font-family="sans-serif" font-size="12px" font-weight="normal" fill="black">r=0.96, p=6.6e-94</text></g></g><path class="foreground" aria-hidden="true" d="" display="none"/></g></g><g class="mark-group role-scope concat_1_group" role="graphics-object" aria-roledescription="group mark container"><g transform="translate(217,0)"><path class="background" aria-hidden="true" d="M0,0h150v180h-150Z" stroke="#ddd" stroke-width="3"/><g><g class="mark-group role-axis" role="graphics-symbol" aria-roledescription="axis" aria-label="X-axis titled 'API_3x' for a linear scale with values from 0 to 10"><g transform="translate(0.5,180.5)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rule role-axis-tick" pointer-events="none"><line transform="translate(0,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(30,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(60,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(90,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(120,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(150,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-label" pointer-events="none"><text text-anchor="start" transform="translate(0,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0</text><text text-anchor="middle" transform="translate(30,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">2</text><text text-anchor="middle" transform="translate(60,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">4</text><text text-anchor="middle" transform="translate(90,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">6</text><text text-anchor="middle" transform="translate(120,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">8</text><text text-anchor="end" transform="translate(150,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">10</text></g><g class="mark-text role-axis-title" pointer-events="none"><text text-anchor="middle" transform="translate(75,34)" font-family="sans-serif" font-size="11px" font-weight="bold" fill="#000" opacity="1">API_3x</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-group role-axis" role="graphics-symbol" aria-roledescription="axis" aria-label="Y-axis titled 'Manual_Qatar' for a linear scale with values from 0 to 10"><g transform="translate(0.5,0.5)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rule role-axis-tick" pointer-events="none"><line transform="translate(0,180)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,144)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,108)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,72)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,36)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,0)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-label" pointer-events="none"><text text-anchor="end" transform="translate(-7,184)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0</text><text text-anchor="end" transform="translate(-7,148)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">2</text><text text-anchor="end" transform="translate(-7,112)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">4</text><text text-anchor="end" transform="translate(-7,76)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">6</text><text text-anchor="end" transform="translate(-7,39.99999999999999)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">8</text><text text-anchor="end" transform="translate(-7,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">10</text></g><g class="mark-text role-axis-title" pointer-events="none"><text text-anchor="middle" transform="translate(-26.572265625,90) rotate(-90) translate(0,-2)" font-family="sans-serif" font-size="11px" font-weight="bold" fill="#000" opacity="1">Manual_Qatar</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-symbol role-mark concat_1_layer_0_marks" role="graphics-object" aria-roledescription="symbol mark container"><path aria-label="API_3x: 10; Manual_Qatar: 9; Statements: a. Association with type I interferon responses; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(150,17.999999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; Manual_Qatar: 3.33333333; Statements: b. Association with type II interferon responses; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,120.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; Manual_Qatar: 5.33333333; Statements: c. Association with type III interferon responses; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(85,84.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; Manual_Qatar: 6; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(130,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; Manual_Qatar: 2; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; Manual_Qatar: 3.66666667; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(95,113.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.33333333333; Manual_Qatar: 3.33333333; Statements: g. Known drug target; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(50.00000000000001,120.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.33333333333; Manual_Qatar: 6.66666667; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(125,59.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; Manual_Qatar: 8.66666667; Statements: a. Association with type I interferon responses; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(130,23.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; Manual_Qatar: 3.66666667; Statements: b. Association with type II interferon responses; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,113.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_Qatar: 4.66666667; Statements: c. Association with type III interferon responses; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(45,95.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_Qatar: 6; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(105,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_Qatar: 2.33333333; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(30,138.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; Manual_Qatar: 5; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(80,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; Manual_Qatar: 2.66666667; Statements: g. Known drug target; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(15,131.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; Manual_Qatar: 6; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(85,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; Manual_Qatar: 8; Statements: a. Association with type I interferon responses; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(130,35.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; Manual_Qatar: 3.33333333; Statements: b. Association with type II interferon responses; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,120.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; Manual_Qatar: 4.33333333; Statements: c. Association with type III interferon responses; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,102.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_Qatar: 5.66666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(105,77.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_Qatar: 2; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(30,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; Manual_Qatar: 4; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(80,108)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; Manual_Qatar: 2.33333333; Statements: g. Known drug target; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(20,138.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; Manual_Qatar: 6; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(90,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; Manual_Qatar: 2; Statements: a. Association with type I interferon responses; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(40,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; Manual_Qatar: 0.66666667; Statements: b. Association with type II interferon responses; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,167.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; Manual_Qatar: 0.66666667; Statements: c. Association with type III interferon responses; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(15,167.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; Manual_Qatar: 2; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(70,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; Manual_Qatar: 0.33333333; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(10,174.00000006000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; Manual_Qatar: 1.33333333; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,156.00000006000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; Manual_Qatar: 0.33333333; Statements: g. Known drug target; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(15,174.00000006000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; Manual_Qatar: 1.66666667; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(40,149.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_Qatar: 5.33333333; Statements: a. Association with type I interferon responses; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,84.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9; Manual_Qatar: 7.66666667; Statements: b. Association with type II interferon responses; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(135,41.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; Manual_Qatar: 2; Statements: c. Association with type III interferon responses; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(70,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_Qatar: 7.33333333; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(120,48.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; Manual_Qatar: 2; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(40,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; Manual_Qatar: 4.33333333; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(80,102.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; Manual_Qatar: 2; Statements: g. Known drug target; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_Qatar: 6.33333333; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,66.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; Manual_Qatar: 3.33333333; Statements: a. Association with type I interferon responses; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(85,120.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; Manual_Qatar: 7.66666667; Statements: b. Association with type II interferon responses; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(95,41.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; Manual_Qatar: 2; Statements: c. Association with type III interferon responses; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_Qatar: 6; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_Qatar: 1.66666667; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(30,149.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_Qatar: 3.66666667; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(75,113.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; Manual_Qatar: 1; Statements: g. Known drug target; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(15,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_Qatar: 5; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(75,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_Qatar: 4.33333333; Statements: a. Association with type I interferon responses; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,102.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.33333333333; Manual_Qatar: 8.66666667; Statements: b. Association with type II interferon responses; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(109.99999999999999,23.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.33333333333; Manual_Qatar: 2.66666667; Statements: c. Association with type III interferon responses; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(65,131.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.33333333333; Manual_Qatar: 7.66666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(125,41.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; Manual_Qatar: 3.33333333; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(35,120.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_Qatar: 5; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(75,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; Manual_Qatar: 1.33333333; Statements: g. Known drug target; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(20,156.00000006000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_Qatar: 6.66666667; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,59.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_Qatar: 7.33333333; Statements: a. Association with type I interferon responses; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(120,48.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_Qatar: 5.66666667; Statements: b. Association with type II interferon responses; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(75,77.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_Qatar: 2.33333333; Statements: c. Association with type III interferon responses; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(45,138.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_Qatar: 5.66666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(105,77.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_Qatar: 1.66666667; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(30,149.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; Manual_Qatar: 4; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(90,108)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; Manual_Qatar: 1.33333333; Statements: g. Known drug target; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(15,156.00000006000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_Qatar: 5.33333333; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(75,84.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.33333333333; Manual_Qatar: 9.33333333; Statements: a. Association with type I interferon responses; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(140,12.000000060000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_Qatar: 4.66666667; Statements: b. Association with type II interferon responses; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(45,95.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; Manual_Qatar: 5.33333333; Statements: c. Association with type III interferon responses; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(80,84.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_Qatar: 7.66666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(120,41.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; Manual_Qatar: 2.66666667; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(35,131.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_Qatar: 5.66666667; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(75,77.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; Manual_Qatar: 5; Statements: g. Known drug target; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(35,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_Qatar: 7.66666667; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(105,41.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.33333333333; Manual_Qatar: 9; Statements: a. Association with type I interferon responses; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(140,17.999999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_Qatar: 5.33333333; Statements: b. Association with type II interferon responses; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(75,84.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_Qatar: 5; Statements: c. Association with type III interferon responses; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(75,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.66666666667; Manual_Qatar: 5.66666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(115.00000000000001,77.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_Qatar: 2; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(45,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; Manual_Qatar: 4.66666667; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(90,95.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_Qatar: 2.66666667; Statements: g. Known drug target; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(30,131.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_Qatar: 6.33333333; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,66.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9; Manual_Qatar: 8.66666667; Statements: a. Association with type I interferon responses; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(135,23.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4; Manual_Qatar: 4; Statements: b. Association with type II interferon responses; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(60,108)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.33333333333; Manual_Qatar: 4.33333333; Statements: c. Association with type III interferon responses; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(65,102.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_Qatar: 5; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(105,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_Qatar: 2; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(30,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; Manual_Qatar: 4.66666667; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(85,95.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; Manual_Qatar: 1.33333333; Statements: g. Known drug target; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,156.00000006000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; Manual_Qatar: 6; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(90,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 10; Manual_Qatar: 10; Statements: a. Association with type I interferon responses; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(150,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_Qatar: 4; Statements: b. Association with type II interferon responses; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(45,108)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; Manual_Qatar: 5.33333333; Statements: c. Association with type III interferon responses; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(90,84.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; Manual_Qatar: 8; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(130,35.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4; Manual_Qatar: 3; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(60,125.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; Manual_Qatar: 5.33333333; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(95,84.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_Qatar: 3.66666667; Statements: g. Known drug target; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(30,113.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.66666666667; Manual_Qatar: 7.66666667; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(115.00000000000001,41.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_Qatar: 1; Statements: a. Association with type I interferon responses; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(45,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_Qatar: 1; Statements: b. Association with type II interferon responses; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(30,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; Manual_Qatar: 1; Statements: c. Association with type III interferon responses; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(15,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_Qatar: 2; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(75,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; Manual_Qatar: 0.33333333; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,174.00000006000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.33333333333; Manual_Qatar: 1.33333333; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(50.00000000000001,156.00000006000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; Manual_Qatar: 0.66666667; Statements: g. Known drug target; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(20,167.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_Qatar: 1; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(45,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.66666666667; Manual_Qatar: 9.33333333; Statements: a. Association with type I interferon responses; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(144.99999999999997,12.000000060000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; Manual_Qatar: 5; Statements: b. Association with type II interferon responses; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(80,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_Qatar: 4.66666667; Statements: c. Association with type III interferon responses; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(75,95.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.33333333333; Manual_Qatar: 6.33333333; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(125,66.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_Qatar: 3.66666667; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(45,113.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_Qatar: 5.66666667; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(105,77.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_Qatar: 3.33333333; Statements: g. Known drug target; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(30,120.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.33333333333; Manual_Qatar: 7; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(109.99999999999999,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.66666666667; Manual_Qatar: 6.66666667; Statements: a. Association with type I interferon responses; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(115.00000000000001,59.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; Manual_Qatar: 3.33333333; Statements: b. Association with type II interferon responses; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,120.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; Manual_Qatar: 3; Statements: c. Association with type III interferon responses; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(35,125.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; Manual_Qatar: 5.33333333; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(95,84.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; Manual_Qatar: 2; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(20,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_Qatar: 4.33333333; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(75,102.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; Manual_Qatar: 2.66666667; Statements: g. Known drug target; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(40,131.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; Manual_Qatar: 5; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(70,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_Qatar: 6.33333333; Statements: a. Association with type I interferon responses; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(105,66.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_Qatar: 4.33333333; Statements: b. Association with type II interferon responses; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(75,102.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.33333333333; Manual_Qatar: 2.66666667; Statements: c. Association with type III interferon responses; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(50.00000000000001,131.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_Qatar: 6; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(120,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_Qatar: 2; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(30,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; Manual_Qatar: 4; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(85,108)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4; Manual_Qatar: 4; Statements: g. Known drug target; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(60,108)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_Qatar: 6; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(105,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_Qatar: 7; Statements: a. Association with type I interferon responses; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(120,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_Qatar: 4; Statements: b. Association with type II interferon responses; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(45,108)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_Qatar: 2.66666667; Statements: c. Association with type III interferon responses; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(30,131.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_Qatar: 4.66666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(105,95.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; Manual_Qatar: 2; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(15,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_Qatar: 4; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(75,108)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; Manual_Qatar: 2; Statements: g. Known drug target; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(10,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; Manual_Qatar: 5.33333333; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(90,84.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; Manual_Qatar: 1; Statements: a. Association with type I interferon responses; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(10,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; Manual_Qatar: 1; Statements: b. Association with type II interferon responses; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(10,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; Manual_Qatar: 1; Statements: c. Association with type III interferon responses; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(10,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; Manual_Qatar: 1.33333333; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(40,156.00000006000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; Manual_Qatar: 0.33333333; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(10,174.00000006000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; Manual_Qatar: 0.66666667; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(35,167.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0; Manual_Qatar: 1; Statements: g. Known drug target; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(0,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; Manual_Qatar: 1.33333333; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(20,156.00000006000002)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 10; Manual_Qatar: 10; Statements: a. Association with type I interferon responses; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(150,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.66666666667; Manual_Qatar: 9.66666667; Statements: b. Association with type II interferon responses; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(144.99999999999997,5.999999940000014)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_Qatar: 6.66666667; Statements: c. Association with type III interferon responses; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(120,59.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.33333333333; Manual_Qatar: 9.66666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(140,5.999999940000014)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; Manual_Qatar: 4.66666667; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(80,95.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_Qatar: 7; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(105,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; Manual_Qatar: 6; Statements: g. Known drug target; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(70,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; Manual_Qatar: 9; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(130,17.999999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9; Manual_Qatar: 8.66666667; Statements: a. Association with type I interferon responses; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(135,23.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; Manual_Qatar: 4.66666667; Statements: b. Association with type II interferon responses; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(85,95.99999994000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4; Manual_Qatar: 4; Statements: c. Association with type III interferon responses; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(60,108)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_Qatar: 6.66666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(120,59.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; Manual_Qatar: 2.66666667; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(40,131.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_Qatar: 5; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; Manual_Qatar: 2.66666667; Statements: g. Known drug target; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,131.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; Manual_Qatar: 6.33333333; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(95,66.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9; Manual_Qatar: 9; Statements: a. Association with type I interferon responses; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(135,17.999999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; Manual_Qatar: 5.33333333; Statements: b. Association with type II interferon responses; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(70,84.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.33333333333; Manual_Qatar: 4.33333333; Statements: c. Association with type III interferon responses; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(50.00000000000001,102.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_Qatar: 7.33333333; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(120,48.00000005999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; Manual_Qatar: 2.66666667; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(35,131.99999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; Manual_Qatar: 5; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(85,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; Manual_Qatar: 3.33333333; Statements: g. Known drug target; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,120.00000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_Qatar: 7; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/></g><g class="mark-text role-mark concat_1_layer_1_marks" role="graphics-object" aria-roledescription="text mark container"><text text-anchor="start" transform="translate(10,14)" font-family="sans-serif" font-size="12px" font-weight="normal" fill="black">r=0.92, p=1.3e-69</text></g></g><path class="foreground" aria-hidden="true" d="" display="none"/></g></g><g class="mark-group role-scope concat_2_group" role="graphics-object" aria-roledescription="group mark container"><g transform="translate(434,0)"><path class="background" aria-hidden="true" d="M0,0h150v180h-150Z" stroke="#ddd" stroke-width="3"/><g><g class="mark-group role-axis" role="graphics-symbol" aria-roledescription="axis" aria-label="X-axis titled 'API_3x' for a linear scale with values from 0 to 10"><g transform="translate(0.5,180.5)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rule role-axis-tick" pointer-events="none"><line transform="translate(0,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(30,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(60,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(90,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(120,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(150,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-label" pointer-events="none"><text text-anchor="start" transform="translate(0,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0</text><text text-anchor="middle" transform="translate(30,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">2</text><text text-anchor="middle" transform="translate(60,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">4</text><text text-anchor="middle" transform="translate(90,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">6</text><text text-anchor="middle" transform="translate(120,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">8</text><text text-anchor="end" transform="translate(150,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">10</text></g><g class="mark-text role-axis-title" pointer-events="none"><text text-anchor="middle" transform="translate(75,34)" font-family="sans-serif" font-size="11px" font-weight="bold" fill="#000" opacity="1">API_3x</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-group role-axis" role="graphics-symbol" aria-roledescription="axis" aria-label="Y-axis titled 'Manual_US' for a linear scale with values from 0 to 10"><g transform="translate(0.5,0.5)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rule role-axis-tick" pointer-events="none"><line transform="translate(0,180)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,144)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,108)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,72)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,36)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,0)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-label" pointer-events="none"><text text-anchor="end" transform="translate(-7,184)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0</text><text text-anchor="end" transform="translate(-7,148)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">2</text><text text-anchor="end" transform="translate(-7,112)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">4</text><text text-anchor="end" transform="translate(-7,76)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">6</text><text text-anchor="end" transform="translate(-7,39.99999999999999)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">8</text><text text-anchor="end" transform="translate(-7,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">10</text></g><g class="mark-text role-axis-title" pointer-events="none"><text text-anchor="middle" transform="translate(-26.572265625,90) rotate(-90) translate(0,-2)" font-family="sans-serif" font-size="11px" font-weight="bold" fill="#000" opacity="1">Manual_US</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-symbol role-mark concat_2_layer_0_marks" role="graphics-object" aria-roledescription="symbol mark container"><path aria-label="API_3x: 10; Manual_US: 10; Statements: a. Association with type I interferon responses; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(150,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; Manual_US: 5.666666667; Statements: b. Association with type II interferon responses; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,77.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; Manual_US: 7.333333333; Statements: c. Association with type III interferon responses; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(85,48.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; Manual_US: 8.666666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(130,23.999999994000014)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; Manual_US: 6; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; Manual_US: 7; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(95,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.33333333333; Manual_US: 6.333333333; Statements: g. Known drug target; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(50.00000000000001,66.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.33333333333; Manual_US: 8; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: DDX58" role="graphics-symbol" aria-roledescription="point" transform="translate(125,35.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; Manual_US: 7.333333333; Statements: a. Association with type I interferon responses; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(130,48.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; Manual_US: 3.666666667; Statements: b. Association with type II interferon responses; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,113.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_US: 5.333333333; Statements: c. Association with type III interferon responses; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(45,84.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_US: 6.333333333; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(105,66.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_US: 4; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(30,108)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; Manual_US: 5.333333333; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(80,84.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; Manual_US: 2.666666667; Statements: g. Known drug target; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(15,131.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; Manual_US: 5; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: DDX60" role="graphics-symbol" aria-roledescription="point" transform="translate(85,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; Manual_US: 7; Statements: a. Association with type I interferon responses; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(130,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; Manual_US: 4.333333333; Statements: b. Association with type II interferon responses; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,102.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; Manual_US: 5.333333333; Statements: c. Association with type III interferon responses; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,84.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_US: 6.333333333; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(105,66.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_US: 3; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(30,125.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; Manual_US: 4.333333333; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(80,102.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; Manual_US: 2.333333333; Statements: g. Known drug target; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(20,138.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; Manual_US: 5; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: DHX58" role="graphics-symbol" aria-roledescription="point" transform="translate(90,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; Manual_US: 1.333333333; Statements: a. Association with type I interferon responses; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(40,156.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; Manual_US: 1; Statements: b. Association with type II interferon responses; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; Manual_US: 1; Statements: c. Association with type III interferon responses; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(15,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; Manual_US: 2; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(70,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; Manual_US: 1; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(10,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; Manual_US: 1.333333333; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,156.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; Manual_US: 1; Statements: g. Known drug target; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(15,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; Manual_US: 1.333333333; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: FBXO6" role="graphics-symbol" aria-roledescription="point" transform="translate(40,156.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_US: 5.333333333; Statements: a. Association with type I interferon responses; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,84.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9; Manual_US: 10; Statements: b. Association with type II interferon responses; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(135,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; Manual_US: 5.333333333; Statements: c. Association with type III interferon responses; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(70,84.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_US: 8.333333333; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(120,30.000000005999993)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; Manual_US: 5.333333333; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(40,84.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; Manual_US: 7; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(80,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; Manual_US: 3.333333333; Statements: g. Known drug target; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,120.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_US: 7.666666667; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: GBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,41.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; Manual_US: 3.666666667; Statements: a. Association with type I interferon responses; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(85,113.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; Manual_US: 9; Statements: b. Association with type II interferon responses; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(95,17.999999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; Manual_US: 4.666666667; Statements: c. Association with type III interferon responses; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,95.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_US: 6.666666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,59.999999993999985)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_US: 4; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(30,108)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_US: 5.333333333; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(75,84.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; Manual_US: 2.333333333; Statements: g. Known drug target; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(15,138.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_US: 6; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: GBP4" role="graphics-symbol" aria-roledescription="point" transform="translate(75,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_US: 3.666666667; Statements: a. Association with type I interferon responses; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,113.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.33333333333; Manual_US: 9.666666667; Statements: b. Association with type II interferon responses; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(109.99999999999999,5.999999994000018)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.33333333333; Manual_US: 4.666666667; Statements: c. Association with type III interferon responses; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(65,95.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.33333333333; Manual_US: 7.666666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(125,41.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; Manual_US: 4.333333333; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(35,102.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_US: 5.666666667; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(75,77.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; Manual_US: 2.666666667; Statements: g. Known drug target; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(20,131.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_US: 7; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: GBP5" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_US: 8; Statements: a. Association with type I interferon responses; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(120,35.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_US: 5.333333333; Statements: b. Association with type II interferon responses; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(75,84.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_US: 5; Statements: c. Association with type III interferon responses; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(45,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_US: 6.666666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(105,59.999999993999985)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_US: 4.666666667; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(30,95.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; Manual_US: 6; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(90,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; Manual_US: 3; Statements: g. Known drug target; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(15,125.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_US: 5.666666667; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IFI35" role="graphics-symbol" aria-roledescription="point" transform="translate(75,77.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.33333333333; Manual_US: 10; Statements: a. Association with type I interferon responses; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(140,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_US: 5.666666667; Statements: b. Association with type II interferon responses; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(45,77.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; Manual_US: 7.666666667; Statements: c. Association with type III interferon responses; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(80,41.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_US: 8.666666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(120,23.999999994000014)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; Manual_US: 6.666666667; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(35,59.999999993999985)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_US: 7.666666667; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(75,41.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; Manual_US: 6.333333333; Statements: g. Known drug target; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(35,66.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_US: 8.333333333; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IFIH1" role="graphics-symbol" aria-roledescription="point" transform="translate(105,30.000000005999993)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.33333333333; Manual_US: 9.333333333; Statements: a. Association with type I interferon responses; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(140,12.000000005999997)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_US: 5.333333333; Statements: b. Association with type II interferon responses; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(75,84.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_US: 6.666666667; Statements: c. Association with type III interferon responses; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(75,59.999999993999985)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.66666666667; Manual_US: 7.666666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(115.00000000000001,41.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_US: 6.333333333; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(45,66.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; Manual_US: 7.333333333; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(90,48.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_US: 4.333333333; Statements: g. Known drug target; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(30,102.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_US: 7; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IFIT2" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9; Manual_US: 9.333333333; Statements: a. Association with type I interferon responses; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(135,12.000000005999997)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4; Manual_US: 4.333333333; Statements: b. Association with type II interferon responses; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(60,102.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.33333333333; Manual_US: 6.333333333; Statements: c. Association with type III interferon responses; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(65,66.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_US: 7.333333333; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(105,48.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_US: 5.666666667; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(30,77.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; Manual_US: 7; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(85,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; Manual_US: 3.333333333; Statements: g. Known drug target; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,120.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; Manual_US: 6.333333333; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IFIT5" role="graphics-symbol" aria-roledescription="point" transform="translate(90,66.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 10; Manual_US: 10; Statements: a. Association with type I interferon responses; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(150,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_US: 5.666666667; Statements: b. Association with type II interferon responses; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(45,77.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; Manual_US: 8; Statements: c. Association with type III interferon responses; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(90,35.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; Manual_US: 9; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(130,17.999999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4; Manual_US: 6.666666667; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(60,59.999999993999985)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; Manual_US: 7.666666667; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(95,41.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_US: 6.666666667; Statements: g. Known drug target; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(30,59.999999993999985)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.66666666667; Manual_US: 8.333333333; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: IRF7" role="graphics-symbol" aria-roledescription="point" transform="translate(115.00000000000001,30.000000005999993)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_US: 1.333333333; Statements: a. Association with type I interferon responses; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(45,156.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_US: 1.333333333; Statements: b. Association with type II interferon responses; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(30,156.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; Manual_US: 1.333333333; Statements: c. Association with type III interferon responses; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(15,156.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_US: 2.333333333; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(75,138.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; Manual_US: 1.666666667; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,149.99999999399998)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.33333333333; Manual_US: 1.666666667; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(50.00000000000001,149.99999999399998)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; Manual_US: 2; Statements: g. Known drug target; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(20,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_US: 2; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: LAP3" role="graphics-symbol" aria-roledescription="point" transform="translate(45,144)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.66666666667; Manual_US: 9.333333333; Statements: a. Association with type I interferon responses; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(144.99999999999997,12.000000005999997)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; Manual_US: 5.666666667; Statements: b. Association with type II interferon responses; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(80,77.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_US: 7; Statements: c. Association with type III interferon responses; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(75,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.33333333333; Manual_US: 8; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(125,35.99999999999999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_US: 6.666666667; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(45,59.999999993999985)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_US: 7.666666667; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(105,41.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_US: 5.666666667; Statements: g. Known drug target; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(30,77.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.33333333333; Manual_US: 7.666666667; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: OAS2" role="graphics-symbol" aria-roledescription="point" transform="translate(109.99999999999999,41.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7.66666666667; Manual_US: 7.666666667; Statements: a. Association with type I interferon responses; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(115.00000000000001,41.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.66666666667; Manual_US: 4.666666667; Statements: b. Association with type II interferon responses; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(54.99999999999999,95.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; Manual_US: 5.666666667; Statements: c. Association with type III interferon responses; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(35,77.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; Manual_US: 6.333333333; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(95,66.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; Manual_US: 5; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(20,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_US: 6; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(75,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; Manual_US: 4.333333333; Statements: g. Known drug target; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(40,102.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; Manual_US: 6.333333333; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: PARP12" role="graphics-symbol" aria-roledescription="point" transform="translate(70,66.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_US: 6.333333333; Statements: a. Association with type I interferon responses; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(105,66.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_US: 5; Statements: b. Association with type II interferon responses; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(75,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.33333333333; Manual_US: 4.333333333; Statements: c. Association with type III interferon responses; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(50.00000000000001,102.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_US: 6.666666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(120,59.999999993999985)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_US: 5; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(30,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; Manual_US: 5.666666667; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(85,77.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4; Manual_US: 5; Statements: g. Known drug target; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(60,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_US: 6.666666667; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: PARP14" role="graphics-symbol" aria-roledescription="point" transform="translate(105,59.999999993999985)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_US: 7.666666667; Statements: a. Association with type I interferon responses; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(120,41.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3; Manual_US: 4.666666667; Statements: b. Association with type II interferon responses; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(45,95.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2; Manual_US: 5.666666667; Statements: c. Association with type III interferon responses; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(30,77.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_US: 6.666666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(105,59.999999993999985)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1; Manual_US: 5; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(15,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5; Manual_US: 6; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(75,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; Manual_US: 4; Statements: g. Known drug target; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(10,108)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6; Manual_US: 6; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: SAMD9L" role="graphics-symbol" aria-roledescription="point" transform="translate(90,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; Manual_US: 0.666666667; Statements: a. Association with type I interferon responses; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(10,167.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; Manual_US: 0.666666667; Statements: b. Association with type II interferon responses; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(10,167.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; Manual_US: 0.666666667; Statements: c. Association with type III interferon responses; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(10,167.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; Manual_US: 1.333333333; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(40,156.000000006)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0.666666666667; Manual_US: 1; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(10,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; Manual_US: 1; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(35,162)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 0; Manual_US: 0.666666667; Statements: g. Known drug target; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(0,167.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.33333333333; Manual_US: 0.666666667; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: SCO2" role="graphics-symbol" aria-roledescription="point" transform="translate(20,167.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 10; Manual_US: 10; Statements: a. Association with type I interferon responses; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(150,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.66666666667; Manual_US: 10; Statements: b. Association with type II interferon responses; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(144.99999999999997,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_US: 9; Statements: c. Association with type III interferon responses; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(120,17.999999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9.33333333333; Manual_US: 10; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(140,0)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.33333333333; Manual_US: 7.666666667; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(80,41.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 7; Manual_US: 8.666666667; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(105,23.999999994000014)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; Manual_US: 7.666666667; Statements: g. Known drug target; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(70,41.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8.66666666667; Manual_US: 9.333333333; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: STAT1" role="graphics-symbol" aria-roledescription="point" transform="translate(130,12.000000005999997)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9; Manual_US: 9; Statements: a. Association with type I interferon responses; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(135,17.999999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; Manual_US: 6; Statements: b. Association with type II interferon responses; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(85,72)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4; Manual_US: 6.333333333; Statements: c. Association with type III interferon responses; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(60,66.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_US: 7.666666667; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(120,41.99999999399999)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.66666666667; Manual_US: 6.333333333; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(40,66.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_US: 7.333333333; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,48.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; Manual_US: 5; Statements: g. Known drug target; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,90)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.33333333333; Manual_US: 7; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: TRIM22" role="graphics-symbol" aria-roledescription="point" transform="translate(95,54.00000000000001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 9; Manual_US: 9; Statements: a. Association with type I interferon responses; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(135,17.999999999999996)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#de2d26" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 4.66666666667; Manual_US: 5.666666667; Statements: b. Association with type II interferon responses; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(70,77.999999994)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fc9272" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 3.33333333333; Manual_US: 6.666666667; Statements: c. Association with type III interferon responses; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(50.00000000000001,59.999999993999985)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#fee5d9" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 8; Manual_US: 8.333333333; Statements: d. Relevance to circulating leukocytes immune biology; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(120,30.000000005999993)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#756bb1" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 2.33333333333; Manual_US: 6.333333333; Statements: e. Used as a biomarker in clinical settings; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(35,66.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#74c476" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 5.66666666667; Manual_US: 7.333333333; Statements: f. Potential value as a blood transcriptional biomarker; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(85,48.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c7e9c0" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 1.66666666667; Manual_US: 5.333333333; Statements: g. Known drug target; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(25.000000000000004,84.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#c994c7" stroke-width="2" opacity="0.7"/><path aria-label="API_3x: 6.66666666667; Manual_US: 7.333333333; Statements: h. Therapeutically relevant for immune system diseases; GeneSymbol: ZBP1" role="graphics-symbol" aria-roledescription="point" transform="translate(100.00000000000001,48.00000000600001)" d="M2.739,0A2.739,2.739,0,1,1,-2.739,0A2.739,2.739,0,1,1,2.739,0" fill="#dd1c77" stroke-width="2" opacity="0.7"/></g><g class="mark-text role-mark concat_2_layer_1_marks" role="graphics-object" aria-roledescription="text mark container"><text text-anchor="start" transform="translate(10,14)" font-family="sans-serif" font-size="12px" font-weight="normal" fill="black">r=0.82, p=1.5e-41</text></g></g><path class="foreground" aria-hidden="true" d="" display="none"/></g></g><g class="mark-group role-legend" role="graphics-symbol" aria-roledescription="legend" aria-label="Symbol legend titled 'Statements' for fill color with 8 values: a. Association with type I interferon responses, b. Association with type II interferon responses, c. Association with type III interferon responses, d. Relevance to circulating leukocytes immune biology, e. Used as a biomarker in clinical settings, ending with h. Therapeutically relevant for immune system diseases"><g transform="translate(608,0)"><path class="background" aria-hidden="true" d="M0,0h263v118h-263Z" pointer-events="none"/><g><g class="mark-group role-legend-entry"><g transform="translate(0,16)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-group role-scope" role="graphics-object" aria-roledescription="group mark container"><g transform="translate(0,0)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M5,0A5,5,0,1,1,-5,0A5,5,0,1,1,5,0" fill="#de2d26" stroke-width="1.5" opacity="0.7"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">a. Association with type I interferon responses</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,13)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M5,0A5,5,0,1,1,-5,0A5,5,0,1,1,5,0" fill="#fc9272" stroke-width="1.5" opacity="0.7"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">b. Association with type II interferon responses</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,26)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M5,0A5,5,0,1,1,-5,0A5,5,0,1,1,5,0" fill="#fee5d9" stroke-width="1.5" opacity="0.7"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">c. Association with type III interferon responses</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,39)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M5,0A5,5,0,1,1,-5,0A5,5,0,1,1,5,0" fill="#756bb1" stroke-width="1.5" opacity="0.7"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">d. Relevance to circulating leukocytes immune biology</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,52)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M5,0A5,5,0,1,1,-5,0A5,5,0,1,1,5,0" fill="#74c476" stroke-width="1.5" opacity="0.7"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">e. Used as a biomarker in clinical settings</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,65)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M5,0A5,5,0,1,1,-5,0A5,5,0,1,1,5,0" fill="#c7e9c0" stroke-width="1.5" opacity="0.7"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">f. Potential value as a blood transcriptional biomarker</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,78)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M5,0A5,5,0,1,1,-5,0A5,5,0,1,1,5,0" fill="#c994c7" stroke-width="1.5" opacity="0.7"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">g. Known drug target</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,91)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M5,0A5,5,0,1,1,-5,0A5,5,0,1,1,5,0" fill="#dd1c77" stroke-width="1.5" opacity="0.7"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">h. Therapeutically relevant for immune system diseases</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-text role-legend-title" pointer-events="none"><text text-anchor="start" transform="translate(0,9)" font-family="sans-serif" font-size="11px" font-weight="bold" fill="#000" opacity="1">Statements</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g></g><path class="foreground" aria-hidden="true" d="" display="none"/></g></g></g></svg>